Carbamate compounds for use in preventing or treating neuropathic pain and cluster and migraine headache-associated pain

Abstract

This invention is directed to a method for preventing or treating neuropathic pain and cluster and migraine headache-associated pain comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I): wherein phenyl is substituted at X with one to five halogen atoms independently selected from the group consisting of fluorine, chlorine, bromine and iodine; and; R 1 , R 2 , R 3 and R 4 are independently selected from the group consisting of hydrogen and C 1 -C 4 alkyl; wherein C 1 -C 4 alkyl is optionally substituted with phenyl (wherein phenyl is optionally substituted with substituents independently selected from the group consisting of hydrogen, halogen, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, amino, nitro and cyano).

1 . A pharmaceutical composition for treating neuropathic pain and cluster headache-associated pain comprising a therapeutically effective amount of a compound of Formula (I): 
     
       
         
         
             
             
         
       
     
     wherein
 phenyl is substituted at X with one to five halogen atoms independently selected from the group consisting of fluorine, chlorine, bromine and iodine; and, 
 R 1 , R 2 , R 3  and R 4  are independently selected from the group consisting of hydrogen and C 1 -C 4  alkyl; wherein C 1 -C 4  alkyl is optionally substituted with phenyl wherein phenyl is optionally substituted with substituents independently selected from the group consisting of halogen, C 1 -C 4  alkyl, C 1 -C 4  alkoxy, amino, nitro and cyano and one or more pharmaceutically acceptable carriers or excipients. 
 
   
   
       2 . A pharmaceutical composition for the treatment of neuropathic pain comprising a therapeutically effective amount of a compound of Formula (I): 
     
       
         
         
             
             
         
       
     
     wherein
 phenyl is substituted at X with one to five halogen atoms independently selected from the group consisting of fluorine, chlorine, bromine and iodine; and, 
 R 1 , R 2 , R 3  and R 4  are independently selected from the group consisting of hydrogen and C 1 -C 4  alkyl; wherein C 1 -C 4  alkyl is optionally substituted with phenyl wherein phenyl is optionally substituted with substituents independently selected from the group consisting of halogen, C 1 -C 4  alkyl, C 1 -C 4  alkoxy, amino, nitro and cyano and one or more pharmaceutically acceptable carriers or excipients. 
 
   
   
       3 . A pharmaceutical composition for treating cluster headache-associated pain comprising a therapeutically effective amount of a compound of Formula (I): 
     
       
         
         
             
             
         
       
     
     wherein
 phenyl is substituted at X with one to five halogen atoms independently selected from the group consisting of fluorine, chlorine, bromine and iodine; and, 
 R 1 , R 2 , R 3  and R 4  are independently selected from the group consisting of hydrogen and C 1 -C 4  alkyl; wherein C 1 -C 4  alkyl is optionally substituted with phenyl wherein phenyl is optionally substituted with substituents independently selected from the group consisting of halogen, C 1 -C 4  alkyl, C 1 -C 4  alkoxy, amino, nitro and cyano and one or more pharmaceutically acceptable carriers or excipients. 
 
   
   
       4 . The pharmaceutical composition of  claim 1  wherein X is chlorine. 
   
   
       5 . The pharmaceutical composition of  claim 1  wherein X is substituted at the ortho position of the phenyl ring. 
   
   
       6 . The pharmaceutical composition of  claim 1  wherein R 1 , R 2 , R 3  and R 4  are selected from hydrogen. 
   
   
       7 . The pharmaceutical composition of  claim 1  wherein the compound of Formula (I) is selected from the group consisting of a racemic mixture of a compound of Formula (I), an enantiomer of a compound of Formula (I) and an enantiomeric mixture wherein an enantiomer of a compound of Formula (I) predominates. 
   
   
       8 . The pharmaceutical composition of  claim 7  wherein an enantiomer of Formula (I) predominates to the extent of about 90% or greater. 
   
   
       9 . The pharmaceutical composition of  claim 7  wherein an enantiomer of Formula (I) predominates to the extent of about 98% or greater. 
   
   
       10 . The pharmaceutical composition of  claim 1  wherein the compound of Formula (I) is a compound of Formula (Ia): 
     
       
         
         
             
             
         
       
     
     wherein
 R 1 , R 2 , R 3  and R 4  are independently selected from the group consisting of hydrogen and C 1 -C 4  alkyl; wherein C 1 -C 4  alkyl is optionally substituted with phenyl wherein phenyl is optionally substituted with substituents independently selected from the group consisting of halogen, C 1 -C 4  alkyl, C 1 -C 4  alkoxy, amino, nitro and cyano. 
 
   
   
       10 . The pharmaceutical composition of  claim 10  wherein R 1 , R 2 , R 3  and R 4  are selected from hydrogen. 
   
   
       11 . The pharmaceutical composition of  claim 10  wherein the compound of Formula (Ia) is selected from the group consisting of a racemic mixture of a compound of Formula (Ia), an enantiomer of a compound of Formula (Ia) and an enantiomeric mixture wherein an enantiomer of a compound of Formula (Ia) predominates. 
   
   
       12 . The pharmaceutical composition of  claim 12  wherein an enantiomer of Formula (Ia) predominates to the extent of about 90% or greater. 
   
   
       13 . The pharmaceutical composition of  claim 12  wherein an enantiomer of Formula (Ia) predominates to the extent of about 98% or greater. 
   
   
       14 . The pharmaceutical composition of  claim 1  wherein the compound of Formula (I) is a compound of Formula (Ib): 
     
       
         
         
             
             
         
       
     
   
   
       16 . The pharmaceutical composition of claim  15  wherein the compound of Formula (Ib) is selected from the group consisting of a racemic mixture of the compound of Formula (Ib), an enantiomer of the compound of Formula (Ib) and an enantiomeric mixture wherein an enantiomer of the compound of Formula (Ib) predominates. 
   
   
       17 . The pharmaceutical composition of  claim 16  wherein an enantiomer of Formula (Ib) predominates to the extent of about 90% or greater. 
   
   
       18 . The pharmaceutical composition of  claim 16  wherein an enantiomer of Formula (Ib) predominates to the extent of about 98% or greater. 
   
   
       19 . The pharmaceutical composition of  claim 1  wherein the compound of Formula (I) is an enantiomer of Formula (Ic) or an enantiomeric mixture wherein the enantiomer of Formula (Ic) predominates: 
     
       
         
         
             
             
         
       
     
   
   
       20 . The pharmaceutical composition of  claim 19  wherein the enantiomer of Formula (Ic) predominates to the extent of about 90% or greater. 
   
   
       21 . The pharmaceutical composition of  claim 19  wherein the enantiomer of Formula (Ic) predominates to the extent of about 98% or greater. 
   
   
       22 . The pharmaceutical composition of  claim 2  wherein the compound of Formula (I) is a compound of Formula (Ib): 
     
       
         
         
             
             
         
       
     
   
   
       23 . The pharmaceutical composition of  claim 22  wherein the compound of Formula (Ib) is selected from the group consisting of a racemic mixture of the compound of Formula (Ib), an enantiomer of the compound of Formula (Ib) and an enantiomeric mixture wherein an enantiomer of the compound of Formula (Ib) predominates. 
   
   
       24 . The pharmaceutical composition of  claim 23  wherein an enantiomer of Formula (Ib) predominates to the extent of about 90% or greater. 
   
   
       25 . The pharmaceutical composition of  claim 23  wherein an enantiomer of Formula (Ib) predominates to the extent of about 98% or greater. 
   
   
       26 . The pharmaceutical composition of  claim 2  wherein the compound of Formula (I) is an enantiomer of Formula (Ic) or an enantiomeric mixture wherein the enantiomer of Formula (Ic) predominates: 
     
       
         
         
             
             
         
       
     
   
   
       27 . The pharmaceutical composition of  claim 26  wherein the enantiomer of Formula (Ic) predominates to the extent of about 90% or greater. 
   
   
       28 . The pharmaceutical composition of  claim 26  wherein the enantiomer of Formula (Ic) predominates to the extent of about 98% or greater. 
   
   
       29 . The pharmaceutical composition of  claim 2  wherein neuropathic pain results from chronic or debilitating conditions. 
   
   
       30 . The pharmaceutical composition of  claim 29  wherein the chronic or debilitating conditions are selected from the group consisting of painful diabetic peripheral neuropathy, post-herpetic neuralgia, trigeminal neuralgia, post-stroke pain, multiple sclerosis-associated pain, neuropathies-associated pain such as in idiopathic or post-traumatic neuropathy and mononeuritis, HIV-associated neuropathic pain, cancer-associated neuropathic pain, carpal tunnel-associated neuropathic pain, spinal cord injury-associated pain, complex regional pain syndrome, fibromyalgia-associated neuropathic pain, lumbar and cervical pain, reflex sympathetic dystrophy, phantom limb syndrome and other chronic and debilitating condition-associated pain syndromes. 
   
   
       31 . The pharmaceutical composition of  claim 26  wherein the therapeutically effective amount is from about 0.01 mg/Kg/dose to about 25 mg/Kg/dose. 
   
   
       32 . The pharmaceutical composition of  claim 3  wherein the compound of Formula (I) is a compound of Formula (Ib): 
     
       
         
         
             
             
         
       
     
   
   
       33 . The pharmaceutical composition of  claim 32  wherein the compound of Formula (Ib) is selected from the group consisting of a racemic mixture of the compound of Formula (Ib), an enantiomer of the compound of Formula (Ib) and an enantiomeric mixture wherein an enantiomer of the compound of Formula (Ib) predominates. 
   
   
       34 . The pharmaceutical composition of  claim 3  wherein an enantiomer of Formula (Ib) predominates to the extent of about 90% or greater. 
   
   
       35 . The pharmaceutical composition of  claim 3  wherein an enantiomer of Formula (Ib) predominates to the extent of about 98% or greater. 
   
   
       36 . The pharmaceutical composition of  claim 3  wherein the compound of Formula (I) is an enantiomer of Formula (Ic) or an enantiomeric mixture wherein the enantiomer of Formula (Ic) predominates: 
     
       
         
         
             
             
         
       
     
   
   
       37 . The pharmaceutical composition of  claim 36  wherein the enantiomer of Formula (Ic) predominates to the extent of about 90% or greater. 
   
   
       38 . The pharmaceutical composition of  claim 36  wherein the enantiomer of Formula (Ic) predominates to the extent of about 98% or greater. 
   
   
       39 . The pharmaceutical composition of  claim 1  wherein the method is a method for slowing or delaying the progression of neuropathic pain and cluster headache-associated pain comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I). 
   
   
       40 . The pharmaceutical composition of  claims 3 ,  7 ,  10 ,  32 ,  36  or  39  wherein the therapeutically effective amount is from about 0.01 mg/Kg/dose to about 25 mg/Kg/dose.